Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials

References

• Alniemi ST, Pang NK, Woog JJ, Bradley EA. Comparison of automated and manual perimetry in patients with blepharoptosis. Ophthal Plast Reconstr Surg. 2013;29:361–363. doi:10.1097/IOP.0b013e31829a7288
   Web of Science ®Google Scholar
• Cahill KV, Burns JA, Weber PA. The effect of blepharoptosis on the field of vision. Ophthal Plast Reconstr Surg. 1987;3:121–125. doi:10.1097/00002341-198703030-00001
   PubMedGoogle Scholar
• McKean-Cowdin R, Varma R, Wu J, Hays RD, Azen SP; Los Angeles Latino Eye Study Group. Severity of visual field loss and health-related quality of life. Am J Ophthalmol. 2007;143:1013–1023. doi:10.1016/j.ajo.2007.02.022
   PubMed Web of Science ®Google Scholar
• Meyer DR, Stern JH, Jarvis JM, Lininger LL. Evaluating the visual field effects of blepharoptosis using automated static perimetry. Ophthalmology. 1993;100:651–658. doi:10.1016/S0161-6420(93)31593-9
   PubMed Web of Science ®Google Scholar
• Finsterer J. Ptosis: causes, presentation, and management. Aesthetic Plast Surg. 2003;27:193–204. doi:10.1007/s00266-003-0127-5
   PubMed Web of Science ®Google Scholar
• Beard C. Muller’s superior tarsal muscle: anatomy, physiology, and clinical significance. Ann Plast Surg. 1985;14:324–333. doi:10.1097/00000637-198504000-00005
   PubMed Web of Science ®Google Scholar
• Freddo TF, Chaum E, eds. Anatomy of the Eye and Orbit: The Clinical Essentials. 1st ed. Philadelphia: Wolters Kluwer Health; 2018.
   Google Scholar
• Hamedani AG, Gold DR. Eyelid dysfunction in neurodegenerative, neurogenetic, and neurometabolic disease. Front Neurol. 2017;8:329. doi:10.3389/fneur.2017.00329
   PubMed Web of Science ®Google Scholar
• Latting MW, Huggins AB, Marx DP, Giacometti JN. Clinical evaluation of blepharoptosis: distinguishing age-related ptosis from masquerade conditions. Semin Plast Surg. 2017;31:5–16. doi:10.1055/s-0037-1598188
   Web of Science ®Google Scholar
• Lim JM, Hou JH, Singa RM, Aakalu VK, Setabutr P. Relative incidence of blepharoptosis subtypes in an oculoplastics practice at a tertiary care center. Orbit. 2013;32:231–234. doi:10.3109/01676830.2013.788673
   PubMedGoogle Scholar
• Sudhakar P, Vu Q, Kosoko-Lasaki O, Palmer M. Upper eyelid ptosis revisited. Am J Clin Med. 2009;6:5–14.
   Google Scholar
• Bacharach J, Lee WW, Harrison AR, Freddo TF. A review of acquired blepharoptosis: prevalence, diagnosis, and current treatment options. Eye (Lond). 2021;35:2468–2481. doi:10.1038/s41433-021-01547-5
   PubMed Web of Science ®Google Scholar
• Forman WM, Leatherbarrow B, Sridharan GV, Tallis RC. A community survey of ptosis of the eyelid and pupil size of elderly people. Age Ageing. 1995;24:21–24. doi:10.1093/ageing/24.1.21
   Web of Science ®Google Scholar
• Hashemi H, Khabazkhoob M, Emamian MH, et al. The prevalence of ptosis in an Iranian adult population. J Curr Ophthalmol. 2016;28:142–145. doi:10.1016/j.joco.2016.04.005
   PubMedGoogle Scholar
• Kim MH, Cho J, Zhao D, et al. Prevalence and associated factors of blepharoptosis in Korean adult population: the Korea National Health and Nutrition Examination Survey. Eye (Lond). 2017;31:940–946. doi:10.1038/eye.2017.43
   PubMed Web of Science ®Google Scholar
• Cahill KV, Bradley EA, Meyer DR, et al. Functional indications for upper eyelid ptosis and blepharoplasty surgery: a report by the American Academy of Ophthalmology. Ophthalmology. 2011;118(12):2510–2517. doi:10.1016/j.ophtha.2011.09.029
   PubMed Web of Science ®Google Scholar
• Pauly M, Sruthi R. Ptosis: evaluation and management. Kerala J Ophthalmol. 2019;31:11–16. doi:10.4103/kjo.kjo_2_19
   Google Scholar
• Battu VK, Meyer DR, Wobig JL. Improvement in subjective visual function and quality of life outcome measures after blepharoptosis surgery. Am J Ophthalmol. 1996;121:677–686. doi:10.1016/S0002-9394(14)70634-8
   Web of Science ®Google Scholar
• Federici TJ, Meyer DR, Lininger LL. Correlation of the vision-related functional impairment associated with blepharoptosis and the impact of blepharoptosis surgery. Ophthalmology. 1999;106:1705–1712. doi:10.1016/S0161-6420(99)90354-8
   PubMed Web of Science ®Google Scholar
• Ho SF, Morawski A, Sampath R, Burns J. Modified visual field test for ptosis surgery (Leicester Peripheral Field Test). Eye (Lond). 2011;25:365–369. doi:10.1038/eye.2010.210
   PubMed Web of Science ®Google Scholar
• Chou E, Liu J, Seaworth C, et al. Comparison of revision rates on anterior- and posterior-approach ptosis surgery: a retrospective review of 1519 cases. Ophthal Plast Reconstr Surg. 2018;34:246–253. doi:10.1097/IOP.0000000000000938
   Web of Science ®Google Scholar
• Esmaeli-Gutstein B, Hewlett BR, Pashby RC, Oestreicher J, Harvey JT. Distribution of adrenergic receptor subtypes in the retractor muscles of the upper eyelid. Ophthal Plast Reconstr Surg. 1999;15:92–99. doi:10.1097/00002341-199903000-00005
   Web of Science ®Google Scholar
• Park SJ, Jang SY, Baek JS, Chin S, Jang JW. Distribution of adrenergic receptor subtypes and responses to topical 0.5% apraclonidine in patients with blepharoptosis. Ophthalmic Plast Reconstr Surg. 2018;34:547–551. doi:10.1097/IOP.0000000000001095
   Web of Science ®Google Scholar
• Skibell BC, Harvey JH, Oestreicher JH, et al. Adrenergic receptors in the ptotic human eyelid: correlation with phenylephrine testing and surgical success in ptosis repair. Ophthalmic Plast Reconstr Surg. 2007;23:367–371. doi:10.1097/IOP.0b013e3181462a2e
   PubMed Web of Science ®Google Scholar
• Hauck MJ, Steele EA, Perry CB. Predictability of the phenylephrine test with regard to eyelid skin appearanc ein patients who undergo Muller muscle-conjunctival resection without blepharoplasty. Ophthal Plast Reconstr Surg. 2019;36:191–193. doi:10.1097/IOP.0000000000001510
   Web of Science ®Google Scholar
• Garibaldi DC, Hindman HB, Grant MP, Iliff NT, Merbs SL. Effect of 0.5% apraclonidine on ptosis in Horner syndrome. Ophthal Plast Reconstr Surg. 2006;22:53–55. doi:10.1097/01.iop.0000196322.05586.6a
   PubMed Web of Science ®Google Scholar
• Kirkpatrick CA, Shriver EM, Clark TE, Kardon RH. Upper eyelid response to topical 0.5% apraclonidine. Ophthal Plast Reconstr Surg. 2018;34:13–19. doi:10.1097/IOP.0000000000000843
   Web of Science ®Google Scholar
• Lee GN, Lin LW, Mehta S, Freitag SK. Response to phenylephrine testing in upper eyelids with ptosis. Digit J Ophthalmol. 2015;21:1–12.
   Google Scholar
• Mendonça TB, Lummertz AP, Bocaccio FJ, Procianoy F. Effect of low-concentration, nonmydriatic selective alpha-adrenergic agonist eyedrops on upper eyelid position. Dermatol Surg. 2017;43:270–274. doi:10.1097/DSS.0000000000000967
   Web of Science ®Google Scholar
• Nagane Y, Utsugisawa K, Suzuki S, et al. Topical naphazoline in the treatment of myasthenic blepharoptosis. Muscle Nerve. 2011;44:41–44. doi:10.1002/mus.22002
   Web of Science ®Google Scholar
• Rehmani A, Mehta I, Smith E. Treatment of ptosis using brimonidine tartrate for anterior laminectomy-induced Horner syndrome. J Neuroophthalmol. 2020;40:95–96. doi:10.1097/WNO.0000000000000826
   Web of Science ®Google Scholar
• Uncini A, De Nicola G, Di Muzio A, et al. Topical naphazoline in treatment of myopathic ptosis. Acta Neurol Scand. 1993;87:322–324. doi:10.1111/j.1600-0404.1993.tb05516.x
   Web of Science ®Google Scholar
• Wijemanne S, Vijayakumar D, Jankovic J. Apraclonidine in the treatment of ptosis. J Neurol Sci. 2017;376:129–132. doi:10.1016/j.jns.2017.03.025
   PubMed Web of Science ®Google Scholar
• Araujo SV, Bond JB, Wilson RP, Moster MR, Schmidt CM Jr., Spaeth GL. Long term effect of apraclonidine. Br J Ophthalmol. 1995;79:1098–1101. doi:10.1136/bjo.79.12.1098
   PubMed Web of Science ®Google Scholar
• Robin AL, Ritch R, Shin D, Smythe B, Mundorf T, Lehmann RP. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group. Trans Am Ophthalmol Soc. 1995;93:421–438.
   PubMedGoogle Scholar
• Stewart WC, Ritch R, Shin DH, Lehmann RP, Shrader CE, van Buskirk EM. The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group. Arch Ophthalmol. 1995;113:287–292. doi:10.1001/archopht.1995.01100030041019
   PubMedGoogle Scholar
• Afrin^® Original oxymetazoline decongestant nasal spray [package insert]. Whippany, NJ: Bayer Healthcare LLC; Revised February 2017.
   Google Scholar
• Druce HM, Ramsey DL, Karnati S, Carr AN. Topical nasal decongestant oxymetazoline (0.05%) provides relief of nasal symptoms for 12 hours. Rhinology. 2018;56:343–350.
   Web of Science ®Google Scholar
• Duzman E, Anderson J, Vita JB, Lue JC, Chen CC, Leopold IH. Topically applied oxymetazoline. Ocular vasoconstrictive activity, pharmacokinetics, and metabolism. Arch Ophthalmol. 1983;101:1122–1126. doi:10.1001/archopht.1983.01040020124022
   Google Scholar
• Visine L.R. (oxymetazoline hydrochloride 0.025%) [package insert]. New Brunswick, NJ: Johnson & Johnson Healthcare Products, Inc.; 2016.
   Google Scholar
• Slonim CB, Foster S, Jaros M, et al. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol. 2020;138:1168–1175. doi:10.1001/jamaophthalmol.2020.3812
   Web of Science ®Google Scholar
• Putterman AM, Fett DR. Müller’s muscle in the treatment of upper eyelid ptosis: a ten-year study. Ophthalmic Surg. 1986;17:354–360.
   PubMedGoogle Scholar
• Putterman AM, Urist MJ. Muller muscle-conjunctiva resection. Technique for treatment of blepharoptosis. Arch Ophthalmol. 1975;93:619–623. doi:10.1001/archopht.1975.01010020595007
   PubMed Web of Science ®Google Scholar
• Haenisch B, Walstab J, Herberhold S, et al. Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010;24:729–739. doi:10.1111/j.1472-8206.2009.00805.x
   Web of Science ®Google Scholar
• Hosten LO, Snyder C. Over-the-counter ocular decongestants in the United States - mechanisms of action and clinical utility for management of ocular redness. Clin Optom. 2020;12:95–105. doi:10.2147/OPTO.S259398
   PubMed Web of Science ®Google Scholar
• Sugden D, Anwar N, Klein D. Rat pineal α1-adrenoceptor subtypes: studies using radioligand binding and reverse transcription-polymerase chain reaction analysis. Br J Pharmacol. 1996;118:1246–1252. doi:10.1111/j.1476-5381.1996.tb15530.x
   Web of Science ®Google Scholar
• Barsegian A, Botwinick A, Reddy HS. The phenylephrine test revisited. Ophthalmic Plast Reconstr Surg. 2018;34:151–154. doi:10.1097/IOP.0000000000000903
   PubMed Web of Science ®Google Scholar
• Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. J Investig Allergol Clin Immunol. 2006;16:148–155.
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Williamson P, Clearie K, Khan F, Lipworth B. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med. 2010;182:19–24. doi:10.1164/rccm.200911-1701OC
   PubMed Web of Science ®Google Scholar
• McAuliffe-Curtin D, Buckley C. Review of alpha adrenoceptor function in the eye. Eye (Lond). 1989;3:472–476. doi:10.1038/eye.1989.71
   PubMed Web of Science ®Google Scholar
• Gobbels MJ, Achten C, Spitznas M. Effect of topically applied oxymetazoline on tear volume and tear flow in humans. Graefes Arch Clin Exp Ophthalmol. 1991;229:147–149. doi:10.1007/BF00170547
   Web of Science ®Google Scholar